Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study-Reference-Cited by-同舟云学术

Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study

Published:2022-06 Issue:6 Volume:22 Page:791-801
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Cerqueira-Silva Thiago,Andrews Jason R,Boaventura Viviane S,Ranzani Otavio T,de Araújo Oliveira Vinicius,Paixão Enny S,Júnior Juracy Bertoldo,Machado Tales Mota,Hitchings Matt D T,Dorion Murilo,Lind Margaret L,Penna Gerson O,Cummings Derek A T,Dean Natalie E,Werneck Guilherme Loureiro,Pearce Neil,Barreto Mauricio L,Ko Albert I,Croda Julio,Barral-Netto Manoel

Publisher

Elsevier BV

Subject

Infectious Diseases

Reference33 articles.

1. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis;Chen;Lancet Glob Health,2021

2. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months;Thomas;N Engl J Med,2021

3. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK;Voysey;Lancet,2021

4. Vaccinating people who have had COVID-19: why doesn't natural immunity count in the US?;Block;BMJ,2021

5. Is one vaccine dose enough if you've had COVID? What the science says;Dolgin;Nature,2021

Cited by 91 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Text mining method to unravel long COVID’s clinical condition in hospitalized patients;Cell Death & Disease;2024-09-13

2. Booster Vaccination with BNT162b2 Improves Cellular and Humoral Immune Response in the Pediatric Population Immunized with CoronaVac;Vaccines;2024-08-15

3. Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study;The Lancet Microbe;2024-08

4. The single-dose Janssen Ad26.COV2.S COVID-19 vaccine elicited robust and persistent anti-spike IgG antibody responses in a 12-month Ugandan cohort;Frontiers in Immunology;2024-05-08

5. Avoidable COVID-19-related deaths and hospitalizations in Brazil, 2020–2023;Vaccine;2024-05